Table IV.
Univariate and multivariate analyses of overall survival in breast cancer cases.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age (years) | ||||||
| >50 | 0.96 | 0.32–2.86 | 0.941 | 0.82 | 0.24–2.81 | 0.754 |
| ≤50 | 1.00 | 1.00 | ||||
| Stage | ||||||
| III/IV | 55.02 | 7.12–425.20 | <0.001 | 115.26 | 13.24–1003.63 | <0.001 |
| I/II | 1.00 | 1.00 | ||||
| Grade | ||||||
| III/IV | 2.56 | 0.79–8.31 | 0.118 | 0.90 | 0.24–3.33 | 0.872 |
| I/II | 1.00 | 1.00 | ||||
| ER | ||||||
| Positive | 0.59 | 0.19–1.81 | 0.359 | 0.80 | 0.19–3.39 | 0.766 |
| Negative | 1.00 | 1.00 | ||||
| HER2 | ||||||
| Positive | 0.72 | 0.22–2.35 | 0.591 | 0.80 | 0.22–2.91 | 0.731 |
| Negative | 1.00 | 1.00 | ||||
| NAMPT | ||||||
| High | 1.34 | 0.41–4.35 | 0.628 | 0.20 | 0.04–0.89 | 0.034 |
| Low | 1.00 | 1.00 | ||||
HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NAMPT, nicotinamide phosphoribosyltransferase.